Denali Therapeutics elects Julian Baker as director; grants registration rights to Baker Brothers funds

Denali Therapeutics Inc.

Julian C. Baker elected as Class II director; 98.0M votes for, 22.9M withheld.
Registration rights agreement with BBA Funds grants resale registration rights; company must file S-3 within 60 days of request.
Ratified Ernst & Young as independent auditor for FY2025; advisory say-on-pay approved with 90.2% of shares represented.

item 1.01item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.